Frovatriptan is a selective 5-HT1B/1D receptor agonist that acts as a potent vasoconstrictor in cerebral blood vessels and inhibits neurogenic inflammation. By binding to these serotonin receptors, it reduces the release of pro-inflammatory neuropeptides and modulates pain transmission, thereby providing therapeutic relief for cluster headache symptoms. Its high receptor affinity and longer half-life compared to other triptans make it effective in managing acute cluster headache episodes.